UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 18.038

Sortiert nach

Advocate Condell touts modernization project

Daily herald (Arlington Heights, Ill. : Arlington Heights ed.), 2024-07-05, p.10

2024

Link zum Volltext

Verfügbarkeit prüfen

New Post-Hoc Analysis from Phase 3 REFLECT Trial Presented at ESMO GI 2024 Explores Efficacy Outcomes with LENVIMA (lenvatinib) Based on Depth of Tumor Response in Unresectable Hepatocellular Carcinoma

PR newswire, 2024-06-27

2024

Link zum Volltext

Verfügbarkeit prüfen

New Efficacy Data for Non-Clear Cell Renal Cell Carcinoma From KEYNOTE-B61 Added to LENVIMA (lenvatinib) US Label Supporting KEYTRUDA + LENVIMA Indication for the First-Line Treatment of Adult Patients With Advanced RCC

PR newswire, 2024-06-27

2024

Link zum Volltext

Verfügbarkeit prüfen

European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab

Business Wire, 2024-06-21

2024

Link zum Volltext

Verfügbarkeit prüfen

FDA Approves Merck's KEYTRUDA (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma

Business Wire, 2024-06-17

2024

Link zum Volltext

Verfügbarkeit prüfen

IMFINZI (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer

Business Wire, 2024-06-17

2024

Link zum Volltext

Verfügbarkeit prüfen

TALVEY (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma

PR newswire, 2024-06-14

2024

Link zum Volltext

Verfügbarkeit prüfen

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

Business Wire, 2024-06-14

2024

Link zum Volltext

Verfügbarkeit prüfen

U.S. Food and Drug Administration Approves Augtyro (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Business Wire, 2024-06-13

2024

Link zum Volltext

Verfügbarkeit prüfen

U.S. Food and Drug Administration Approves Augtyro[TM] , for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Business Wire, 2024-06-13

2024

Link zum Volltext

Verfügbarkeit prüfen

Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer

Business Wire, 2024-06-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer

Business Wire, 2024-06-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Jemperli rectal cancer

Business Wire, 2024-06-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Tolmar Announces Results From Inaugural Landmark Survey of US Physicians To Assess Current State of Testosterone Replacement Therapy (TRT) and the Impact on Practices and Patient Care

PR newswire, 2024-06-02

2024

Link zum Volltext

Verfügbarkeit prüfen

A Survey of Deep Learning Techniques and Applications in Bioengineering: A Latin American Perspective

Advances in Bioengineering and Clinical Engineering, p.612-632

Link zum Volltext

Verfügbarkeit prüfen

EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024

Business Wire, 2024-05-31

2024

Link zum Volltext

Verfügbarkeit prüfen

Gilead Provides Update on Phase 3 TROPiCS-04 Study

Business Wire, 2024-05-30

2024

Link zum Volltext

Verfügbarkeit prüfen

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Business Wire, 2024-05-29

2024

Link zum Volltext

Verfügbarkeit prüfen

FDA Grants Priority Review to Merck's Application for KEYTRUDA (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Business Wire, 2024-05-29

2024

Link zum Volltext

Verfügbarkeit prüfen

Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival

Business Wire, 2024-05-28

2024

Link zum Volltext

Verfügbarkeit prüfen

AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024

PR newswire, 2024-05-28

2024

Link zum Volltext

Verfügbarkeit prüfen

Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)

Business Wire, 2024-05-28

2024

Link zum Volltext

Verfügbarkeit prüfen

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant at the ASCO 2024 Annual Meeting

PR newswire, 2024-05-24

2024

Link zum Volltext

Verfügbarkeit prüfen

BRUKINSA Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL

Business Wire, 2024-05-24

2024

Link zum Volltext

Verfügbarkeit prüfen

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting

PR newswire, 2024-05-24

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 18.038

Suche als RSS-Feed

Aktive Filter

PublikationsformArtikel

PublikationsformNewsletter-Artikel

PublikationsformBerichte

ThemaCellular Biology

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(269)
Mit Volltextzugriff
(5.671)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

ProQuest Dissertations & Theses A&I
(9.124)
Ebook Central Perpetual and DDA
(6.381)
eBooks on EBSCOhost
(6.023)
Nexis
(1.883)
ScienceDirect eBooks
(1.458)
Wiley Online Library All Obooks
(1.164)
Taylor & Francis eBooks A-Z
(1.050)
Springer Book Series
(213)
Ingenta
(151)
MEDLINE
(119)
The Electronic Journals Library
(76)
Single Journals
(63)
EBSCOhost Business Source Ultimate
(51)
De Gruyter eBooks
(33)
Journals@Ovid Complete
(23)
SAGE Publications
(20)
Elsevier ScienceDirect Journals Complete
(17)
Wiley Journals
(12)
JSTOR Complete Journals
(12)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Business Wire
(941)
Pr Newswire
(642)
Monthly Prescribing Reference
(247)
Drug Topics
(23)
M2 Presswire
(15)
The Lancet
(10)
Mlo. Medical Laboratory Observer
(8)
Journal Of Diagnostic Medical Sonography
(7)
The Clinical Advisor
(7)
Good Housekeeping
(6)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Advocate Condell touts modernization project

New Post-Hoc Analysis from Phase 3 REFLECT Trial Presented at ESMO GI 2024 Explores Efficacy Outcomes with LENVIMA (lenvatinib) Based on Depth of Tumor Response in Unresectable Hepatocellular Carcinoma

New Efficacy Data for Non-Clear Cell Renal Cell Carcinoma From KEYNOTE-B61 Added to LENVIMA (lenvatinib) US Label Supporting KEYTRUDA + LENVIMA Indication for the First-Line Treatment of Adult Patients With Advanced RCC

European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab

FDA Approves Merck's KEYTRUDA (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma

IMFINZI (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer

TALVEY (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

U.S. Food and Drug Administration Approves Augtyro (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

U.S. Food and Drug Administration Approves Augtyro[TM] , for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer

Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer

Jemperli rectal cancer

Tolmar Announces Results From Inaugural Landmark Survey of US Physicians To Assess Current State of Testosterone Replacement Therapy (TRT) and the Impact on Practices and Patient Care

A Survey of Deep Learning Techniques and Applications in Bioengineering: A Latin American Perspective

EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024

Gilead Provides Update on Phase 3 TROPiCS-04 Study

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

FDA Grants Priority Review to Merck's Application for KEYTRUDA (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival

AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024

Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant at the ASCO 2024 Annual Meeting

BRUKINSA Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting

Aktive Filter

Suchergebnisse filtern